CG Oncology Accelerates PIVOT-006 Phase 3 Timeline: Topline Data for Intermediate-Risk NMIBC Expected Nearly a Year Early
PIVOT-006 Phase 3 Timeline Moved Forward: Topline Data Coming in 1H 2026
CG Oncology has announced an expedited timeline for its pivotal Phase 3 PIVOT-006 clinical trial, evaluating cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Thanks to rapid enrollment across more than 90 sites, topline data are now expected in the first half of 2026—ahead of prior expectations by nearly a year.
First Randomized Phase 3 Trial in Intermediate-Risk NMIBC Broadens Treatment Landscape
PIVOT-006 represents the first randomized Phase 3 study of its kind to compare adjuvant intravesical cretostimogene against simple surveillance following tumor removal in patients with intermediate-risk NMIBC. Its design captures the broadest range of eligible patient types per AUA/SUO guidelines, including those with high-grade, solitary lesions smaller than 3 centimeters.
| Study Name | Patient Population | Comparator | Estimated Enrollment | Expected Topline Data |
|---|---|---|---|---|
| PIVOT-006 | Intermediate-risk NMIBC | Cretostimogene vs. Surveillance | 360+ | 1H 2026 |
Rapid Enrollment Signals High Unmet Need
Enrollment for PIVOT-006 was completed significantly faster than anticipated. Over 360 patients were enrolled from a U.S. intermediate-risk population estimated at over 50,000 individuals. The trial’s reach across both academic and community sites supports its real-world relevance, emphasizing the high demand for effective new therapies in this setting. Currently, there are no FDA-approved adjuvant options for these patients.
Cretostimogene: A Potential Backbone Immunotherapy for Bladder Cancer
Cretostimogene grenadenorepvec, the therapy under study, is an investigational, intravesically delivered oncolytic immunotherapy. To date, it has been studied in more than 400 patients across the development pipeline, which includes two Phase 3 trials (BOND-003 for high-risk and PIVOT-006 for intermediate-risk NMIBC). While cretostimogene is not yet FDA-approved and its safety and efficacy remain under investigation, CG Oncology is actively broadening patient access through a North American Expanded Access Program for BCG-unresponsive cases.
What’s Next: Market Implications for CG Oncology and IR NMIBC Patients
The advancement of the PIVOT-006 timeline boosts the company’s potential to establish the first FDA-approved adjuvant therapy option for intermediate-risk NMIBC. If the study demonstrates positive results, CG Oncology could be well positioned to address a significant gap in bladder cancer care and target a large patient population in the U.S.
Key Takeaway: Investors Eye Early Data and Potential Market Expansion
With topline results expected in the first half of 2026, CG Oncology is on pace to deliver pivotal clinical data ahead of schedule. Given the size of the intermediate-risk NMIBC patient pool and absence of FDA-approved adjuvant therapies, the trial’s outcome could have important implications for both patients and the company’s growth trajectory. Stakeholders may want to monitor PIVOT-006’s progress and upcoming regulatory developments closely.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI